Last reviewed · How we verify
Condyloma acuminatum — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Aldara | IMIQUIMOD | Bausch Health | imiquimod | 7,8-dihydro-8-oxoguanine triphosphatase | 1997-01-01 | |
| Condylox | podophyllotoxin | Actavis Labs Ut Inc | podophyllotoxin | Glucocorticoid receptor | 1990-01-01 | |
| Intron A | INTERFERON ALFA-2B | Merck & Co. | Interferon alpha | 1986-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 3 drugs in Condyloma acuminatum
- Actavis Labs Ut Inc · 1 drug in Condyloma acuminatum
- Bausch Health · 1 drug in Condyloma acuminatum
- Merck & Co. · 1 drug in Condyloma acuminatum
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Condyloma acuminatum:
- Condyloma acuminatum treatment updates — RSS
- Condyloma acuminatum treatment updates — Atom
- Condyloma acuminatum treatment updates — JSON
Cite this brief
Drug Landscape (2026). Condyloma acuminatum — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/condyloma-acuminatum. Accessed 2026-06-10.
Related
- Condyloma acuminatum full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing